Autopsy report · NCT05016804
Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell IV Infusion for Systemic Sclerosis
Cause of deathFutility
“Inadequate treatment response observed in preliminary data did not justify enrolling further study participants”
Life of this trial
- Registered 11 months before it started.
- Ran for about 3 years 5 months before it stopped.
- 20 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 1
- Sponsor
- The Foundation for Orthopaedics and Regenerative Medicine
- Sponsor type
- University, hospital or other
- Conditions
- Systemic Sclerosis
- Interventions
- AlloRx
- Participants
- 20
- Sites
- 2
- Countries
- Antigua and Barbuda, Argentina
Trials that died the same way
- Efficacy of the Infusion of Donor Plasma in COVID-19 Infection
“Lack of efficacy of treatment tested” - Xenogenic Keratoplasty From Porcine Cornea
“there was not enough patients recruited in this study” - BIIB023 Proof-of-Concept Study in Participants With Lupus Nephritis
“Results from pre-specified criteria did not demonstrate sufficient efficacy to warrant continuation of the study.” - A Study of Panobinostat (LBH589) as Second-Line Therapy in Patients With Chronic Graft-Versus-Host Disease
“A decision was made to not move forward with the study. No participants were enrolled or treated.” - H-29 DELTA Multihole TT Study.
“Lack of progress in fulfilling the Study activities, including the lack of enrollment of participants”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.